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Abstract: Drug resistance is a primary hindrance for efﬁ  ciency of chemotherapy. To investi-
gate whether Fe3O4-magnetic nanoparticles (Fe3O4-MNPs) loaded with adriamycin (ADM) and 
tetrandrine (Tet) would play a synergetic reverse role in multidrug resistant cell, we prepared the 
drug-loaded nanoparticles by mechanical absorption polymerization to act with K562 and one of 
its resistant cell line K562/A02. The survival of cells which were cultured with these conjugates 
for 48 h was observed by MTT assay. Using cells under the same condition described before, we 
took use of ﬂ  uorescence microscope to measure ﬂ  uorescence intensity of intracellular ADM at an 
excitation wavelength of 488 nm. P-glycoprotein (P-gp) was analyzed with ﬂ  ow cytometer. The 
expression of mdr1 mRNA was measured by RT-PCR. The results showed that the growth inhibition 
efﬁ  cacy of both the two cells increased with augmenting concentrations of Fe3O4-MNPs which were 
loaded with drugs. No linear correlation was found between ﬂ  uorescence intensity of intracellular 
adriamycin and augmenting concentration of Fe3O4-MNPs. Tet could downregulate the level of 
mdr-1 gene and decrease the expression of P-gp. Furthermore, Tet polymerized with Fe3O4-MNPs 
reinforced this downregulation, causing a 100-fold more decrease in mdr1 mRNA level, but did 
not reduce total P-gp content. Our results suggest that Fe3O4-MNPs loaded with ADM or Tet can 
enhance the effective accumulation of the drugs in K562/A02. We propose that Fe3O4-MNPs loaded 
with ADM and Tet probably have synergetic effect on reversal in multidrug resistance.
Keywords: magnetic nanoparticles, tetrandrine, adriamycin, multidrug resistance reversal, 
leukemia K562/A02
Introduction
The multidrug resistance (MDR) phenotype, induced by the over expression of ATP-
binding cassette (ABC) transporters, a family of transporter proteins, is responsible 
for chemotherapy failure in patients with hematological malignancies. This phenotype 
is generally due to the expression of the MDR1 gene encoding a 170 kDa ABC trans-
porter P-glycoprotein (P-gp) in the cell membrane of cells pumping chemotherapeutic 
drugs out of cells. Once MDR emerges, chemotherapy is not effective when using 
high doses of drugs enough to overcome the resistance, even toxic effects are caused 
and the resistance mechanism could be further stimulated (Choi 2005). Modulation 
of P-gp activity by chemotherapy is limited because of toxicity and poor speciﬁ  city. 
To reverse the resistance mechanism and reduce side effects during chemotherapy, a 
promising approach is to combine a conventional chemotherapy with new strategies 
such as chemosensitizers to inhibit ABC transporters, nanotechnology for targeted 
drug delivery (Page and Takimoto 2004).
In vitro and in vivo studies have demonstrated that tetrandrine (Tet), a kind of herbal 
constituent, possesses potent and speciﬁ  c activity in reversing P-gp-mediated drug 
resistance (Fu et al 2004; Zhou et al 2004; Zhu et al 2005). This naturally occurring International Journal of Nanomedicine 2008:3(2) 278
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compound may be used as a chemosensitizer in the treatment 
of P-gp-mediated MDR malignancies (Liu et al 2003).
Nanotechnology and nanoscience have developed fast 
during the last few decades. The most important clinical 
applications of nanotechnology are probably in pharmaceuti-
cal development (Thrall 2004). The in vitro cytotoxicity test 
revealed that Fe3O4-magnetic nanoparticles (Fe3O4-MNPs) 
exhibited excellent biocompatibility (Win et al 2003; Cheng 
et al 2005), furthermore, no carcinogenic effects have been 
demonstrated for the magnetite particles (Kosar et al 2004).
To date, few studies have approached the mechanism of 
drug-loaded nanoparticles affecting an drug-resistant leuke-
mia cell (Laurand et al 2004). In our experiment, we prepared 
Fe3O4-MNPs loaded with ADM and Tet to interfere MDR of 
K562/A02 cell. By analyzing several biological parameters, 
we found that ADM and Tet-loaded Fe3O4-MNPs would 
contribute to a synergetic reverse in multidrug resistant cells 
K562/A02, that may owe to the accumulation of drugs caused 
by its polymerization with Fe3O4-MNPs; Besides, Tet-loaded 
Fe3O4-MNPs enhances MDR1 downregulation but doesn’t 
reduce the total P-gp content.
Materials and methods
Main reagents
Adriamycin (ADM, doxorubicin) stock solution 50 mmol/l 
(Sigma Aldrich Ltd., St. Louis, MO, USA) was prepared with 
0.01 mol/l phosphate buffer saline (PBS) (pH 7.4). Tet was 
kindly provided by Yintao Pharmaceutical (Jiangxi, China) 
which would be diluted also with 0.01 mol/l PBS (pH 7.4). 
All reagents used in this study are analytical grade.
Cell lines and culture conditions
K562 cells, derived from human leukemic cells of a chronic 
myeloid leukemia patient in blastic crisis, had been constantly 
preserved in our laboratory. K562/A02 cell line (a gift from 
Institute of Hematology, Chinese Academy of Medical Sci-
ences, Tianjin, China) was incubated in the medium containing 
1 µg/ml ADM for maintaining the resistant characteristics. We 
kept K562/A02 in medium without ADM for 2 weeks before 
using these cells. Both the cells were cultured at 37 °C in a 5% 
CO2 incubator with 100% humidity in RPMI 1640 medium 
(Gibco/BRL, Bethesda, MD, USA) supplemented with 10% 
heat-inactivated fetal bovine serum (FBS) (Sijiqing, Hangzhou, 
China), 100 U/ml penicillin, and 100 µg/ml streptomycin.
Preparation of drug-loaded nanoparticles
Fe3O4-MNPs were prepared by the electrochemical deposition 
under oxidizing conditions (EDOC), where the magnetization 
and the size of Fe3O4-MNPs was found to be 25.6 × 10−3 emu/mg 
and ca. 30 nm, respectively (Zhang et al 2006). Before applied 
in the present experiment, the Fe3O4 magnetite nanoparticles 
were well-distributed in RPMI 1640 medium freshly added 
with 10% heat-inactivated FBS by using ultrasound treatment 
in order to obtain Fe3O4-MNPs colloidal suspension. ADM 
conjugated with Fe3O4-MNPs (Fe3O4-MNPs-ADM) or ADM 
and Tet co-conjugated with Fe3O4-MNPs (Fe3O4-MNPs-ADM-
Tet) were prepared by mechanical absorption polymerization 
referring to previously reported (Bennis et al 1994; Gao et al 
2004). We also investigated the temperature effect and have 
chosen 37 °C or 4 °C for the polymerization process. Brieﬂ  y, 
different concentrations (V/V), Fe3O4-MNPs (0.05, 0.1, 0.2, 
0.4) were respectively added under mechanical stirring to 
200 µl of an aqueous medium with certain concentration 
of ADM (Fe3O4-MNPs-ADM0.05, Fe3O4-MNPs-ADM0.1, 
Fe3O4-MNPs-ADM0.2, Fe3O4-MNPs-ADM0.4) that in the 
ﬁ  nal nanoparticle and cell suspension was 50 µmol/l (pH 7.4) 
or with ADM and Tet (Fe3O4-MNPs-ADM-Tet0.05, Fe3O4-
MNPs-ADM-Tet0.1, Fe3O4-MNPs-ADM-Tet0.2, Fe3O4-
MNPs-ADM-Tet0.4) that its final concentration was 10 
µmol/l (pH 7.4). At different temperatures (37 °C, 4 °C), the 
overall polymerization process lasted for 24 h. Besides, ADM 
50 µmol/l, Fe3O4-MNPs 0.2 and Tet 10 µmol/l were taken as 
positive controls. RPMI 1640 medium was regarded as blank 
control and cells with no intervention were negative control.
MTT assay
Exponentially growing cells (1.5 × 105/ml) were suspended 
in 200 µl of culture medium on 96-well culture plate contain-
ing different concentrations Fe3O4-MNPs and other control 
groups which had been demonstrated above. The survival of 
cells which were incubated with these conjugates for 48 h 
at 37 °C was observed through 3-(4,5-dimethylthiazol-2-yl)- 
2,5-diphenyltetrazolium bromide (MTT) reagent (Sigma). 
The growth inhibition efﬁ  cacy (GIE) of cells was determined 
as follows: (1-A of tests cells/A of blank control) × 100%. 
The experiments were repeated at least three times.
Fluorescence microscopy study
As described before, cells (1.5 × 105/ml) were incubated with 
ADM polymerized with different concentrations of Fe3O4-
MNPs for 48 h at 37 °C, followed by centrifugation at 1000 
r/min for 5 min. The resulting supernatant fractions were then 
discarded. Cells were washed twice with ice-cold PBS and 
re-suspended in 200 µl PBS in order to measured ﬂ  uorescence 
intensity (FI) of intracellular ADM at a wavelength of 488 nm 
under ﬂ  uorescence microscope in triplicate different visual International Journal of Nanomedicine 2008:3(2) 279
Reversal in multidrug resistance by magnetic nanoparticles
ﬁ  elds at random. FI was quantitated through Image J software 
and was made a curve to analyze liner regression.
Flow cytometry study
To detect P-gp expression, cell suspensions (1.0 × 106) after 
treated for 48 h were washed twice with PBS and centrifuga-
tion at 1000 r/min for 5 min (Kan et al 1998; Geromin et al 
2004). Then the cells were incubated either with the mono-
clonal antibody (MoAb) P-gp-PE (20 µl) (Becton Dickinson, 
Mountain View, CA, USA) or the mouse isotype-matched 
control IgG2a-PE (20 µl) (Becton Dickinson) at 4 °C for 30 
min. After washed with PBS twice, the cells were resuspended 
in PBS 400 µl and ﬂ  uorescence distributions were generated 
by a FACS Calibur ﬂ  ow cytometry (Becton Dickinson). P-
gp expression were given as the ration of P-gp MoAb mean 
ﬂ  uorescence divided by control MoAb ﬂ  uorescence.
Reverse transcription-polymerase chain 
reaction (RT- PCR)
Total cellular RNA was extracted from K562/A02 cell line 
with TRIzol reagent (Gibco/BRL) and quantiﬁ  ed by UV absor-
bance spectroscopy and 1.5% agarose gel. Each lane contained 
RNA from the cells grown with exposure to ADM (50 µmol/l), 
Fe3O4-MNPs (0.2), Tet (10 µmol/l), Tet (1 µmol/l) loaded 
Fe3O4-MNPs (0.2), Tet (5 µmol/l) loaded Fe3O4-MNPs (0.2) 
and Tet (10 µmol/l) loaded Fe3O4-MNPs (0.2), respectively. 
Negative control was also set for a lane. The reverse tran-
scription reaction was performed using TaKaRa RNA PCR 
kit (AMV) Ver.3.0 (Dalian, China). The newly synthesized 
cDNA was ampliﬁ  ed by PCR (TaKaRa). Primers involved 
in were: the mdr1 primer (forward: 5'-TGG TTT GAT GTG 
CAC GAT GTT GGG-3'; reverse: 5'-AGA TCA GCA GGA 
AAG CAG CAC CTA-3'); for the β-actin primer (forward: 
5'-TGA CGG GGT CAC CCA CAC TGT GCC CAT CTA-3'; 
reverse: 5'-CTA GAA GCA TTT GCG GTG GAC GAT GGA 
GGG-3') (Gan et al 2005). The ampliﬁ  ed PCR products were 
436 bp and 661 bp for MDR1 and β-actin, respectively. The 
conditions for PCR were as follows: 94 °C predenaturation 
for 5 min, 94 °C denaturation for 30 s, 56 °C annealing for 30 
s, 72 °C extension for 1 min followed by 72 °C 10 min for 35 
cycles. Aliquots of the PCR product were electrophoresed on 
1.5% agarose gels and PCR fragments were visualized by UV 
illumination (UVP GDS7500 Gel, Upland, CA, USA) stained 
by ethidium bromide (Thörn et al 2005). The ﬂ  uorescence 
intensity of β-actin fragments served as the criterion for the 
MDR1 fragments. Densitometric analysis was performed 
using the electrophoresis image analysis system Smart View 
2000 software (Furi, Shanghai, China).
Statistical analysis
Data were analyzed using the Statistical Package for Social 
Science (SPSS Release 11.5; SPSS Inc., Chicago, IL, USA). 
Differences were evaluated using the one-way ANOVA, 
Student’s t-test or paired t-test. A P value   0.05 or   0.01 
was considered signiﬁ  cant. The results were expressed as the 
mean ± SD of data obtained in triplicate. The liner regression 
between GIE of the two cells and increasing concentrations 
Fe3O4-MNPs loaded with ADM or ﬂ  uorescence intensity of 
K562/A02 intracellular ADM and increasing concentrations 
Fe3O4-MNPs loaded with ADM was estimated using simple 
regression analyze (Microsoft Excel; Microsoft, Redmond, 
WA, USA).
Results
Microscope image of cells with different 
treatments
ADM was polymerized with Fe3O4-MNPs at 37 °C or 4 °C 
for 24 h before that was added in K562 or K562/A02 cultured 
at 37 °C for 48 h in a 5% CO2 incubator with 100% humidity 
in RPMI 1640 medium. It is observed that ADM polymer-
ized with Fe3O4-MNPs aggregated inside the two kinds of 
malignant hemopathic cells obviously (Figure 1; Figure 2).
Cell survival
According to MTT assay, the GIE of both the two cell 
lines increased with augmenting concentrations of Fe3O4-
MNPs which were loaded with drugs: for K562, positive 
liner regression existed between GIE of the cell line and 
increasing concentrations Fe3O4-MNPs loaded with ADM 
(r2   0.95, P   0.05) (Figure 3). In contrast, there wasn’t 
good liner regression between those in K562/A02 cell line 
(Figure 4). Furthermore, the GIE of K562 was signiﬁ  cantly 
higher than that of K562/A02 (P   0.01). It was inferred 
that better polymerization temperature was 4 °C rather than 
37 °C from MTT results (P   0.05).
Fluorescence intensity of intracellular ADM
At a wavelength of 488nm, ADM was excited to emit a 
575 nm wavelength spontaneously which was orange red 
seen by ﬂ  uorescence microscope of low power lens (×600) 
and high power lens (×2400), where ﬂ  uorescence intensity of 
K562/A02 intracellular ADM could be recorded and analyzed 
(Figure 5; Figure 6).
P-glycoprotein (P-gp) expression
Tet or different concentrations of Tet polymerized 0.1 Fe3O4-
MNPs at 4 °C for 48 h were incubated with K562/A02 cells International Journal of Nanomedicine 2008:3(2) 280
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for 48 h while Fe3O4-MNPs were incubated with the cells as 
control (Sun et al 2007). To determine whether Tet or Tet-
loaded Fe3O4-MNPs could inﬂ  uence P-gp, ﬂ  ow cytometry 
was performed and it was indicated the total expression 
content of P-gp was decreased by 24% with Tet, in contrast, 
Fe3O4-MNPs loaded with any concentration of Tet we took 
in the experiment seemed no quantity degression of P-gp 
(Figure.7)
MDR1 mRNA content
Different concentrations of Tet polymerized with Fe3O4-MNPs 
all reinforced down-regulation of MDR1 mRNA content sig-
niﬁ  cantly, causing a 100-fold more decrease in MDR1 mRNA 
level and Tet single used was brought less down-regulation 
than the same concentration of Tet polymerized with Fe3O4-
MNPs; nevertheless, ADM or Fe3O4-MNPs single used had 
no obvious effect on MDR1 mRNA (Figure 8).
Figure 1 Optical inverted microscope image of K562 incubating with different concentration of Fe3O4-magnetic nanoparticles polymerized with ADM for 48 h (original 
magniﬁ  cation ×600, polymeria ztion condition: 4 °C, 24 h). (a) negative control (K562). (b) K562 + ADM (50 µmol/l). (c) K562 + Fe3O4-MNPs0.2. (d) K562 + Fe3O4-MNPs-
ADM0.05. (e) K562 + Fe3O4-MNPs-ADM0.1. (f) K562 + Fe3O4-MNPs-ADM0.2. (g) K562 + Fe3O4-MNPs-ADM0.4.
Figure 2 Optical inverted microscope image of K562/A02 incubating with different concentration of Fe3O4-magnetic nanoparticles polymerized with ADM for 48 h. (original mag-
niﬁ  cation ×2400, polymeriaztion condition: 4 °C 24 h). (a) negative control (K562/A02). (b) K562/A02+ADM (50 µmol/l). (c) K562/A02 + Fe3O4-MNPs0.2. (d) K562/A02 + ADM + 
Tet (10 µmol/l). (e) K562/A02 + Fe3O4-MNPs-ADM0.05. (f) K562/A02 + Fe3O4- MNPs-ADM0.1. (g) K562/A02 + Fe3O4-MNPs-ADM0.2. (h) K562/A02 + Fe3O4-MNPs-ADM0.4. 
(i) K562/A02 + Fe3O4-MNPs-ADM-Tet0.05. (j) K562/A02 + Fe3O4-MNPs-ADM-Tet0.1. (k) K562/A02 + Fe3O4-MNPs-ADM-Tet0.2. (l) K562/A02 + Fe3O4-MNPs-ADM-Tet0.4.International Journal of Nanomedicine 2008:3(2) 281
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Discussion
Reversal in MDR is considered to be the most important 
for the cancer chemotherapy in clinical. The problems 
of overcoming resistance could be resolved by the use 
of the some drugs that could overcome the resistance 
mechanism. These substances would reverse resistance 
against anticancer drugs to eventually being sensitized for 
anticancer drugs, so they are called chemosensitizers or 
MDR reverters. As a result, reversal in MDR is equal to 
chemosensitizing. Researchers have been seeking for low 
toxic and high efﬁ  cient MDR reverters in MDR reversal. 
Any access which could increase the effective concentration 
of intracellular chemotherapeutic agent is available. The 
propensity of macrophages of the reticuloendothelial system 
for rapid recognition and clearance of particulate matter 
has provided a rational approach to macrophage targeting 
with nanoparticles loaded with drugs (Moghimi et al 2005; 
Baker 2006). The feature has contribution to treating hema-
tologic malignancies. Due to the unique properties of some 
biocompatible nanoparticles, they are designed for new 
approaches to drug-targeting delivery, controlled release 
and so on (Song et al 2006). As one of the most commonly 
used magnetic nanoparticles, Fe3O4-MNPs are gained more 
easily than other MNPs and they may aggregate in water 
or tissue ﬂ  uid spontaneously with good biocompatibility 
and low toxicity (Dresco 1999; Willner and Willner 2002; 
Thomas and Sayre 2005). Moreover, Fe3O4-MNPs are found 
readily to interact with proteins (Chen and Liao 2002). Tet 
which is regarded to be a potent inhibitor of P-gp has been 
conﬁ  rmed to be a kind of block agent of Ca2+ channels with 
little cytotoxicity (Liu et al 1990; Mitterdorfer et al 1998; 
Xu et al 2003). It will be used as a chemosensitizers in 
Figure 3 GIE of K562 cell line by increasing concentrations Fe3O4-MNPs loaded with ADM or ADM and Tet. (a) After Fe3O4-MNPs polymerized with ADM at 37 °C for 24 h, 
the ADM loaded Fe3O4-MNPs inhibited cells proliferation more with the increasing concentrations Fe3O4-MNPs, so did incorporation of ADM and Tet-loaded Fe3O4-MNPs , 
R2 = 0.9996 and 0.9805 respectively, P   0.05. Comparatively, GIE of K562 acting with ADM or Fe3O4-MNPs single used was 73.67 ± 3.00% and 50.56 ± 6.07% respectively. 
(b) The similar polymerization at 4 °C for 24 h was done, R2 = 0.9956 and 0.9891 respectively, P   0.05. Comparatively, GIE of K562 acting with ADM or Fe3O4-MNPs single 
used was 70.42 ± 1.88% and 21.86 ± 3.80% respectively.
Figure 4 GIE of K562/A02 cell line by increasing concentrations Fe3O4-MNPs loaded with ADM or ADM and Tet. (a) After Fe3O4-MNPs polymerized with ADM, the ADM 
loaded Fe3O4-MNPs inhibited cells proliferation the most between Fe3O4-MNPs concentrations of 0.1~0.2 at 37 °C for 24 h,, so was the cell growth under the polymerization at 
4 °C for 24 h. (b) There was a similar tendency in cell growth under Fe3O4-MNPs co-polymerized with ADM and Tet. It’s easily observed that GIE under polymerization at 4 °C 
was signiﬁ  cantly higher than that at 37 °C(P   0.05). Comparatively, GIE of K562/A02 acting with ADM, Fe3O4-MNPs single used or ADM and Tet was 34.69 ± 8.49%, 29.41 ± 
11.21%, and 64.03 ± 10.13% respectively at 37 °C, 51.53 ± 11.21% 6.78 ± 11.67% and 77.8 ± 12.54%, respectively at 4 °C.International Journal of Nanomedicine 2008:3(2) 282
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Figure 5 Fluorescence view of K562/A02 intracellular ADM at a wavelength of 488 nm in scope of low power lens (×600) (Figure 7e, 7g, 7i, 7k, 7m, 7o, 7q, 7s) and high power 
lens (×2400) (Figure 7a~7d, 7f, 7h, 7j, 7l, 7n, 7p, 7r, 7t). The polymerization of Fe3O4-MNPs loaded with ADM or ADM and Tet was at 37 °C for 24 h. (a) negative control (K562/
A02). (b) Fe3O4-MNPs 0.2. (c) ADM. (d) Tet. (e), (f) Fe3O4-MNPs 0.05 loaded with ADM. (i), (j) Fe3O4-MNPs 0.1 loaded with ADM. (m),(n): Fe3O4-MNPs 0.2 loaded with ADM. 
(q),(r) Fe3O4-MNPs 0.4 loaded with ADM. (g), (h) Fe3O4-MNPs 0.05 loaded with ADM and Tet. (k), (l) Fe3O4-MNPs 0.1 loaded with ADM and Tet. (o),(p): Fe3O4-MNPs 0.2 
loaded with ADM and Tet. (s),(t) Fe3O4-MNPs 0.4 loaded with ADM and Tet.
P-glycoprotein-mediated ADM resistance (Xu et al 1999; 
Wang et al 2005).
In our experiment, we ﬁ  nd that Fe3O4-MNPs loaded with 
ADM can enhance the effective accumulation of ADM in 
K562/A02 cells, therefore, GIE of K562/A02 and K562 cell 
lines both increase obviously when cells are incubated with 
Fe3O4-MNPs polymerized with ADM or co-polymerized with 
ADM and Tet. It is observed that Fe3O4-MNPs co-polymerized 
with ADM and Tet are the most cytotoxic than any other polym-
erized forms and any other single used drug. Drugs polymerized 
with Fe3O4-MNPs have shown more chemosensitizing activity 
than the drugs alone. It’s also observed that the temperature at 4 
°C is better for the polymerization and the optimal concentration 
of Fe3O4-MNPs (V/V) for K562 is not the same as that of K562/
A02. In K562, there is positive liner® correlation between 
GIE and increasing concentrations Fe3O4-MNPs loaded with 
ADM or ADM and Tet, but no liner correlation is observed 
for those in K562/A02. The rational behind this may be due to 
the multidrug resistance of K562/A02 if compared with that of 
K562. It is known that the anticancer drug can easily enter the 
intracellular cells of K562 with little drug resistant. However, 
in K562/A02 cells, the anticancer drug could be readily pumped International Journal of Nanomedicine 2008:3(2) 283
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Figure 6 Fluorescence intensity of K562/A02 intracellular ADM. The polymerization of Fe3O4-MNPs loaded with ADM or ADM and Tet was at 37 °C for 24 h. (a) Fe3O4-mag-
netic nanoparticles polymerized with ADM (b) Fe3O4-magnetic nanoparticles polymerized with ADM and Tet. No linear correlation was found between ﬂ  uorescence intensity 
of intracellular adriamycin and augmenting concentration of Fe3O4-MNPs.The strongest ﬂ  uorescence intensity was at Fe3O4-MNPs concentrations of 0.1~0.2. For K562/A02, 
ADM single or with Tet accumulated less than that loaded Fe3O4-MNPs.
Figure 7 P-glycoprotein (P-gp) expression of K562/A02 cell line by 0.1 Fe3O4-MNPs loaded with different concentrations of Tet (the polymerization condition: 4 °C, 48 h). 
(a)The mouse isotype-matched IgG2a-PE was used as negative control, P-gp was 2.61%. (b)~(f) The monoclonal antibody (MoAb) P-gp-PE was applied in detecting P-gp. (b)The 
total expression P-gp of K562/A02 was 99.95%. (c) Merely 0.1 Fe3O4-MNPs were incubated with cells, P-gp was 99.88% with no change. (d) Merely Tet (10 µmol/l 1) were 
incubated with cells, P-gp was signiﬁ  cantly decreased to 76.37%. (e) Fe3O4-MNPs loaded with low concentration of Tet (1 µmol/l 1), P-gp was 99.71% with no obvious change. 
(f) Fe3O4-MNPs loaded with high concentration of Tet (10 µmol/l 1), P-gp was 99.69% with no obvious change. 
out or degraded by other drug-resistant mechanisms as soon 
as it reaches the K562/A02 cells. So the effective intracellular 
concentration of ADM is inﬂ  uenced by much interference for 
K562/A02 cells. Thus, that no liner regression exists in the 
latter situation is easily understood.
K562/A02 cell line has been proved to be resistant to 
ADM and characterized with P-gp and MDR1 high expres-
sion (Yang et al 1995). ADM, a chemotherapeutic agent, has 
little effect on P-gp and MDR1, while Tet could down-regu-
late the level of MDR1 gene and decrease the expression of International Journal of Nanomedicine 2008:3(2) 284
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P-gp (Chen et al 2005). Our study has demonstrated that Tet 
polymerized with Fe3O4-MNPs may increase this down-regu-
lation, but can’t reduce P-gp on quantity. Quantity or content 
but not function of P-gp can be detected by ﬂ  ow cytometry. 
This probably infers that Fe3O4-MNPs combining with P-
gp may block the pump function of P-gp, which means the 
pump function of P-gp is cut down but not the quantity of 
P-gp (Cuvier et al 1992; Henry-Toulme et al 1995). Nanopar-
ticles loaded with anticancer drug could readily approach 
the cell membrane, leading to drug concentrations at the cell 
surface higher than those obtained with the same amount of 
drug diluted in the culture medium, leading in turn to higher 
intracellular drug concentration (Hu et al 1996; Soma et al 
2000). Not only have Fe3O4-MNPs the ability to block P-gp 
function, but also have the potent in aggregation and drug-
capsulation (Wong et al 2006a, 2006b). This may be the 
reason that Fe3O4-MNPs which have no cytotoxicity to cells 
and no reversal in multidrug resistance are able to enhance 
ADM or Tet effective concentration intracellularly (Colin de 
Verdière et al 1994). In K562/A02, ADM polymerized with 
Fe3O4-MNPs is more chemosensitizing than ADM alone, 
for it bypasses the multidrug resistance. The chemotherapy 
effectiveness could be further improved with the help of 
synergetic action of ADM and Tet co-polymerization with 
Fe3O4-MNPs, since 10 µmol/l Tet has both capacity in cyto-
toxic potency and reversal in multidrug resistant mechanisms. 
Thus, Tet polymerized with Fe3O4-MNPs causes a 100-fold 
more decrease in MDR1 mRNA level, but did not reduce 
total P-gp content for the combining of Fe3O4-MNPs and 
P-gp, which could be attributed to the P-gp being blockaded 
by Fe3O4-MNPs.
Conclusions
In summary, a new strategy of mechanical absorption polym-
erizing is established to make Fe3O4-magnetic nanoparticles 
load with chemotherapeutic agent ADM and(or) chemo-
sensitizer Tet. Our study demonstrates that temperature 
inﬂ  uenced the effectiveness of the polymerization process. 
Figure 8 MDR1 mRNA content of K562/A02 cell line by different interferes. (The polymerization condition: 4 °C, 48 h) Lane 1 was total mdr1 mRNA isolated from K562/A02 
as negative control. Analyzed density of DNA was 61572. Lane 2 and Lane 3 were from the cells treated with ADM 50 µmol/l and 0.1 Fe3O4-MNPs respectively. The result 
showed 55588 and 60514 with no signiﬁ  cant change compared with Lane 1. Lane 4 was interfered with Tet 10 µmol/l. The result showed 55588 with signiﬁ  cant change compared 
with Lane 1 (P   0.05). From lane 5 to lane 7 were MDR1 mRNA extracted from K562/A02 incubated with low Tet-, medium Tet- and high Tet-loaded 0.1 Fe3O4-MNPs mdr1 
mRNA was signiﬁ  cantly decreased by over 100-fold.International Journal of Nanomedicine 2008:3(2) 285
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That 4 °C is better for the polymerization than 37 °C is also 
observed in this study. Our observations indicate that the 
polymerizing process can be controlled easily and stably. 
In addition, it appears that drug(s) polymerized with Fe3O4-
magnetic nanoparticles deﬁ  nitely have curative effect on 
multidrug resistance by drug accumulating on the basis of 
certain change of some protein and gene. Tet polymerized 
with Fe3O4-MNPs may increase down-regulation of the level 
of MDR1 mRNA, but Fe3O4-MNPs can’t reduce P-gp on 
quantity, suggesting that P-gp function is probably blocked 
off. Totally, Fe3O4-MNPs loaded with ADM and Tet have 
synergetic effect on reversal in multidrug resistance, which 
may be promising for future in vivo studies even in clinic.
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